Aesica Pharmaceuticals S.r.l. has announced the launch of a QAD integrated serialization system at its site in Pianezza to comply with change from China’s Food and Drug Administration (CFDA). The new requirements brought forward by CFDA cut the serialization implementation deadline to from 12 months to three months.
In partnership with QAD, a provider of enterprise software solutions, Aesica reports that the company implemented a solution that assured serialization compliance for two pharmaceutical products for the Chinese market.
The new requirements are designed to maintain customer safety, while fighting drug counterfeiting, streamlining the recall process, and minimizing financial loss. The project involved upgrading and utilizing a serialization module developed in QAD Enterprise Applications that allows Aesica Pharmaceuticals S.r.I. to identify individual packaging down to the smallest sellable unit sizes and aggregate individual unit serial numbers as packages are bundled, boxed and placed on shipping pallets. Aesica Pianezza can seamlessly track and trace each single pack of medication and report serial numbers to the required government agencies for a small number of products once they have been produced and imported.
Source: Aesica Pharmaceuticals